Public Meeting on Patient-Focused Drug Development for Sarcopenia
On April 6, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the on the impact of sarcopenia on daily life and patient views on treatment approaches.
Date:
April 6, 2017
Time:
1:00 p.m. - 5:00 p.m.
Location:
Tommy Douglas Conference Center
10000 New Hampshire Ave.
Silver Spring, MD 20903
Registration:
To register for this meeting, visit: Patient-Focused Drug Development Public Meeting for Sarcopenia Event Brite--]){kind=small}
website.
Registration to attend the meeting must be received by April 6, 2017.
Webcast Information:
Public Docket:
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.
FDA is interested in patient responses to the questions listed in the Federal Register Notice.
Access the public docket here: Docket Information
Meeting Materials
- Meeting Agenda
- Meeting Slides
- Federal Register
- The Voice of the Patient: Sarcopenia
- Webinar: Background on FDA and Patient-Focused Drug Development
- Meeting Recording
- Meeting Transcript: Thursday, April 6, 2017